Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
G
314130
vs
K
KOSPI 200
Over the past 12 months, Genome&Company Inc has underperformed KOSPI 200, delivering a return of +46% compared to KOSPI 200's +56% growth.
Stocks Performance
314130 vs KOSPI 200
Performance Gap
314130 vs KOSPI 200
Performance By Year
314130 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genome&Company Inc
Glance View
Genome&Company is a South Korean biotech company focused on the microbiome, the community of bacteria that live in and on the human body. It develops drug candidates and related technologies aimed mainly at cancer treatment, especially therapies that try to improve how patients respond to immuno-oncology drugs. The company also works on probiotic and skin-microbiome products through partnerships and product development. Its customers are mostly pharmaceutical partners, research collaborators, and, depending on the product line, consumers and healthcare channels. Genome&Company makes money by developing and out-licensing drug candidates, supplying technology or research services, and selling microbiome-related health and beauty products where commercialized. In simple terms, it sits between early-stage science and the companies that can turn that science into medicines or consumer products. What makes its business different is that it is not a classic drug maker focused on mass production. Instead, it uses microbiome research to build proprietary drug pipelines and partner with larger players that can handle late-stage development, regulation, and commercialization. That means its value comes from owning promising scientific platforms and turning them into licensed programs, partnerships, and products.